Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.81 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12194756 | 0.91 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL12219205 | 0.91 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL2509912 | 0.91 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL1914129 | 0.90 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL29385091 | 0.90 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL14829529 | 0.90 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL2509742 | 0.90 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL6382804 | 0.87 | ADORA3 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL21136921 | 0.86 | ADORA3 (0.60) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL21136562 | 0.86 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0601322-A2 | Adenosindeaminase inhibitor | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |